Sentiment-Signal
20,4
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
23.1
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 14.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 30.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | nt Report on Form 8-K and is incorporated in this Item 5.02 by reference. Item 5.03 Amendments to Articles of Incorpor |
| 30.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | forth in Item 1.01 above is incorporated in this Item 5.02 by reference. Item 9.01 Financial Statements and Exhibits. |
| 07.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | nt Report on Form 8-K and is incorporated in this Item 5.02 by reference. Item 5.07 Submission of Matters to a Vote of S |
| 08.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
Stammdaten
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Unternehmen & Branche
| Name | FATE THERAPEUTICS INC |
|---|---|
| Ticker | FATE |
| CIK | 0001434316 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | 31189P102 |
|---|---|
| ISIN | US31189P1021 |
| Typ | Common Stock |
| Marktkapitalisierung | 162,8 Mio. USD |
| Beta | 2,24 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 6,646,000 | -136,315,000 | -1.15 | 318,937,000 | 207,184,000 |
| 2025-09-30 | 10-Q | 1,741,000 | -32,250,000 | -0.27 | 343,671,000 | 234,066,000 |
| 2025-06-30 | 10-Q | 1,907,000 | -34,070,000 | -0.29 | 371,632,000 | 261,364,000 |
| 2025-03-31 | 10-Q | 1,629,000 | -37,621,000 | -0.32 | 398,670,000 | 288,409,000 |
| 2024-12-31 | 10-K | 13,631,000 | -186,262,000 | -1.64 | 440,694,000 | 318,726,000 |
| 2024-09-30 | 10-Q | 3,074,000 | -47,678,000 | -0.40 | 494,970,000 | 362,326,000 |
| 2024-06-30 | 10-Q | 6,772,000 | -38,427,000 | -0.33 | 528,817,000 | 396,982,000 |
| 2024-03-31 | 10-Q | 1,925,000 | -48,004,000 | -0.47 | 569,892,000 | 426,115,000 |
| 2023-12-31 | 10-K | 63,533,000 | -160,928,000 | -1.64 | 506,217,000 | 368,417,000 |
| 2023-09-30 | 10-Q | 1,944,000 | -45,170,000 | -0.46 | 543,788,000 | 402,777,000 |
| 2023-06-30 | 10-Q | 933,000 | -52,755,000 | -0.54 | 584,757,000 | 437,755,000 |
| 2023-03-31 | 10-Q | 58,980,000 | -18,881,000 | -0.19 | 630,336,000 | 477,472,000 |
| 2022-12-31 | 10-K | 96,300,000 | -281,721,000 | -2.91 | 705,561,000 | 483,939,000 |
| 2022-09-30 | 10-Q | 14,981,000 | -83,563,000 | -0.86 | 749,349,000 | 518,003,000 |
| 2022-06-30 | 10-Q | 18,549,000 | -76,105,000 | -0.79 | 807,059,000 | 580,483,000 |
| 2022-03-31 | 10-Q | 18,414,000 | -65,690,000 | -0.68 | 858,386,000 | 633,393,000 |
| 2021-12-31 | 10-K | 55,846,000 | -212,151,000 | -2.24 | 921,455,000 | 678,838,000 |
| 2021-09-30 | 10-Q | 14,225,000 | -43,308,000 | -0.45 | 984,571,000 | 730,332,000 |
| 2021-06-30 | 10-Q | 13,412,000 | -55,133,000 | -0.58 | 1,015,666,000 | 752,071,000 |
| 2021-03-31 | 10-Q | 11,142,000 | -45,089,000 | 1,045,964,000 | 790,095,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 12,872,946 | 0 | 12,872,946 | 12,648,957 | Neu | +100,0% | |
| BlackRock, Inc. | 10,176,487 | 0 | 10,176,487 | 9,999,415 | Neu | +100,0% | |
| VANGUARD GROUP INC | 8,971,347 | 0 | 8,971,347 | 8,818,834 | Neu | +100,0% | |
| JOHNSON & JOHNSON | 3,379,064 | 0 | 3,379,064 | 3,320,268 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 2,468,348 | 0 | 2,468,348 | 2,425,764 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 2,360,881 | 0 | 2,360,881 | 2,319,802 | Neu | +100,0% | |
| STATE STREET CORP | 2,265,217 | 0 | 2,265,217 | 2,225,802 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 1,734,064 | 0 | 1,734,064 | 1,703,891 | Neu | +100,0% | |
| Vestal Point Capital, LP | 1,725,000 | 0 | 1,725,000 | 1,694,985 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 1,577,478 | 0 | 1,577,478 | 1,550,034 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 1,435,040 | 0 | 1,435,040 | 1,410,070 | Neu | +100,0% | |
| AQR CAPITAL MANAGEMENT LLC | 1,162,005 | 0 | 1,162,005 | 1,141,787 | Neu | +100,0% | |
| MORGAN STANLEY | 916,946 | 0 | 916,946 | 900,990 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 842,807 | 0 | 842,807 | 828,142 | Neu | +100,0% | |
| Monaco Asset Management SAM | 830,000 | 0 | 830,000 | 815,558 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 784,628 | 0 | 784,628 | 770,975 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 782,536 | 0 | 782,536 | 768,920 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 732,670 | 0 | 732,670 | 719,921 | Neu | +100,0% | |
| DAFNA Capital Management LLC | 550,000 | 0 | 550,000 | 540,430 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 522,617 | 0 | 522,617 | 513,523 | Neu | +100,0% | |
| UBS Group AG | 403,524 | 0 | 403,524 | 396,664 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 386,091 | 0 | 386,091 | 379,176 | Neu | +100,0% | |
| Invesco Ltd. | 379,025 | 0 | 379,025 | 372,430 | Neu | +100,0% | |
| XTX Topco Ltd | 364,738 | 0 | 364,738 | 358,392 | Neu | +100,0% | |
| BARCLAYS PLC | 308,542 | 0 | 308,542 | 303,173 | Neu | +100,0% | |
| Quadrature Capital Ltd | 298,082 | 0 | 298,082 | 292,895 | Neu | +100,0% | |
| Man Group plc | 261,172 | 0 | 261,172 | 256,628 | Neu | +100,0% | |
| Graham Capital Management, L.P. | 195,579 | 0 | 195,579 | 192,176 | Neu | +100,0% | |
| Schonfeld Strategic Advisors LLC | 192,682 | 0 | 192,682 | 189,328 | Neu | +100,0% | |
| ALLIANCEBERNSTEIN L.P. | 187,700 | 0 | 187,700 | 184,434 | Neu | +100,0% | |
| WELLS FARGO & COMPANY/MN | 172,283 | 0 | 172,283 | 169,285 | Neu | +100,0% | |
| LPL Financial LLC | 169,816 | 0 | 169,816 | 166,861 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 151,107 | 0 | 151,107 | 148,388 | Neu | +100,0% | |
| Assenagon Asset Management S.A. | 148,653 | 0 | 148,653 | 146,066 | Neu | +100,0% | |
| RHUMBLINE ADVISERS | 146,761 | 0 | 146,761 | 144,253 | Neu | +100,0% | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 135,000 | 0 | 135,000 | 132,651 | Neu | +100,0% | |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 95,185 | 0 | 95,185 | 122,789 | Neu | +100,0% | |
| IEQ CAPITAL, LLC | 121,501 | 0 | 121,501 | 119,387 | Neu | +100,0% | |
| Connor, Clark & Lunn Investment Management Ltd. | 111,227 | 0 | 111,227 | 109,292 | Neu | +100,0% | |
| State of Tennessee, Department of Treasury | 90,000 | 0 | 90,000 | 107,100 | Neu | +100,0% | |
| HSBC HOLDINGS PLC | 97,684 | 0 | 97,684 | 96,238 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 91,679 | 0 | 91,679 | 89,846 | Neu | +100,0% | |
| Shay Capital LLC | 70,000 | 0 | 70,000 | 68,782 | Neu | +100,0% | |
| SEI INVESTMENTS CO | 67,643 | 0 | 67,643 | 66,474 | Neu | +100,0% | |
| GROUP ONE TRADING LLC | 56,231 | 0 | 56,231 | 55,252 | Neu | +100,0% | |
| INTECH INVESTMENT MANAGEMENT LLC | 51,660 | 0 | 51,660 | 50,761 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 43,436 | 0 | 43,436 | 42,680 | Neu | +100,0% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 35,658 | 0 | 35,658 | 35,038 | Neu | +100,0% | |
| Focus Partners Wealth | 31,966 | 0 | 31,966 | 31,409 | Neu | +100,0% | |
| Corient Private Wealth LLC | 29,830 | 0 | 29,830 | 29,312 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-09 | TAHL CINDY | Officer, See Remarks | Open Market Sale | -10,589 | 1.06 | -11,275.17 | -107,9% | |
| 2026-01-09 | Valamehr Bahram | Director, Officer, President and CEO | Open Market Sale | -5,190 | 1.07 | -5,557.45 | -53,2% | |
| 2025-08-04 | TAHL CINDY | Officer, See Remarks | Open Market Sale | -9,037 | 1.06 | -9,572.89 | -91,6% | |
| 2025-08-04 | Valamehr Bahram | Director, Officer, President and CEO | Open Market Sale | -14,466 | 1.06 | -15,396.16 | -147,3% |
Fail-to-Deliver (6 Monate)
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-03-24 | 31 | 1,15 | 36 |
| 2026-03-17 | 794 | 1,16 | 921 |
| 2026-02-26 | 4.127 | 1,48 | 6.108 |
| 2026-02-24 | 265 | 1,51 | 400 |
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| Redmile Group, LLC | 12,872,946 | 12,648,957 | 20.92 |
| BlackRock, Inc. | 10,176,487 | 9,999,415 | 16.54 |
| VANGUARD GROUP INC | 8,971,347 | 8,818,834 | 14.59 |
| JOHNSON & JOHNSON | 3,379,064 | 3,320,268 | 5.49 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,468,348 | 2,425,764 | 4.01 |
| RENAISSANCE TECHNOLOGIES LLC | 2,360,881 | 2,319,802 | 3.84 |
| STATE STREET CORP | 2,265,217 | 2,225,802 | 3.68 |
| TWO SIGMA INVESTMENTS, LP | 1,734,064 | 1,703,891 | 2.82 |
| Vestal Point Capital, LP | 1,725,000 | 1,694,985 | 2.80 |
| DIMENSIONAL FUND ADVISORS LP | 1,577,478 | 1,550,034 | 2.56 |
| GOLDMAN SACHS GROUP INC | 1,435,040 | 1,410,070 | 2.33 |
| AQR CAPITAL MANAGEMENT LLC | 1,162,005 | 1,141,787 | 1.89 |
| MORGAN STANLEY | 916,946 | 900,990 | 1.49 |
| JANE STREET GROUP, LLC | 842,807 | 828,142 | 1.37 |
| Monaco Asset Management SAM | 830,000 | 815,558 | 1.35 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 784,628 | 770,975 | 1.28 |
| CITADEL ADVISORS LLC | 782,536 | 768,920 | 1.27 |
| NORTHERN TRUST CORP | 732,670 | 719,921 | 1.19 |
| DAFNA Capital Management LLC | 550,000 | 540,430 | 0.89 |
| MILLENNIUM MANAGEMENT LLC | 522,617 | 513,523 | 0.85 |